TScan Therapeutics, Inc. financial data

Symbol
TCRX on Nasdaq
Location
880 Winter Street, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 829 % +25.9%
Debt-to-equity 57.6 % -16.5%
Return On Equity -63.8 % -6.7%
Return On Assets -40.5 % -14.4%
Operating Margin -2.07K % -127%

Shares

Label TTM Value / Value Unit Change %
Weighted Average Number of Shares Outstanding, Basic 130M shares +14.4%
Weighted Average Number of Shares Outstanding, Diluted 130M shares +14.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.96M USD -42.9%
Research and Development Expense 118M USD +21.8%
General and Administrative Expense 33.2M USD +23.2%
Operating Income (Loss) -144M USD -29.3%
Net Income (Loss) Attributable to Parent -137M USD -31%
Earnings Per Share, Basic -1 USD/shares -108%
Earnings Per Share, Diluted -1 USD/shares -108%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 169M USD -30%
Marketable Securities, Current 48.7M USD -12.4%
Assets, Current 221M USD -26.2%
Property, Plant and Equipment, Net 9.52M USD +25%
Operating Lease, Right-of-Use Asset 61.1M USD +0.24%
Assets 299M USD -20.4%
Accounts Payable, Current 4.54M USD +45.9%
Employee-related Liabilities, Current 3.66M USD +3.89%
Liabilities, Current 31.3M USD -18.8%
Operating Lease, Liability, Noncurrent 58.1M USD +1.94%
Other Liabilities, Noncurrent 113K USD
Liabilities 122M USD +1.84%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4K USD
Retained Earnings (Accumulated Deficit) -446M USD -44.2%
Stockholders' Equity Attributable to Parent 177M USD -30.8%
Liabilities and Equity 299M USD -20.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 174M USD -29.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37M USD -16.7%
Operating Lease, Liability, Current 6.29M USD +74%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 3.11M USD -17%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%